Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVIS

This article was originally published in The Gray Sheet

Executive Summary

Cardiovascular Imaging Systems receives FDA clearance to market the GuideView ultrasound imaging/delivery catheter. The 4 French GuideView incorporates the company's "common-lumen technology which allows low-profile therapeutic and imaging devices to use the distal portion of the catheter interchangeably." CVIS, which does not intend to market the device until late 1994, says it is evaluating use of the device with several angioplasty balloons, including Cordis' Orion and Advanced Cardiovascular Systems' Slalom. CVIS currently is concentrating on ramping up production of its MicroView 2.9 diagnostic catheter, which received FDA clearance on June 29. The company anticipates commercial distribution of the MicroView in October.

You may also be interested in...



Moderna Gets To Watch And Learn From Pfizer’s COVID-19 Vaccine Advisory Committee

US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.

Sabinsa Reaches Out To US Regulators To Squeeze Fake Vitamin C Out Of Ingredient Markets

Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”

Novavax May Seek COVID-19 Vaccine Emergency Authorization In US Based On UK Data

With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel